Replicor将在HEPDART 2019上展示最新的临床数据

StephenW

Replicor to present updated clinical data at HEPDART 2019

MONTREAL, December 5th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced that three presentations will be made at the 2019 HEPDART meeting to be held December 8-12th , 2019 in Kauai, HI, USA.

One oral presentation on December 9th and two posters on December 10th will cover the following:

1)      Disclosure of the final completed follow-up results from the REP 301-LTF and REP 401 studies, showing high rates of stable functional cure of HBV and HDV infection.

2)      Analysis showing the safe and beneficial relationship between transaminase flares occurring in the absence of HBsAg during NAP-based combination and the ability of this on-therapy milestone to predict virologic control and functional cure of HBV and HDV infection.

Replicor’s presentations will be made available following their publication on the company’s website at www.replicor.com/science/conference-presentations.  For further information about the 2019 HEPDART Meeting: https://hepdart.com/

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

StephenW

复制品将在HEPDART 2019上展示最新的临床数据

蒙特利尔，2019年12月5日-专门针对慢性乙型和丁型肝炎感染患者进行功能治疗的私有生物制药公司Replicor Inc.宣布将于2019年12月8日至12日举行的2019 HEPDART会议上进行三场演讲在美国夏威夷考艾岛

12月9日的一份口头报告和12月10日的两张海报将涵盖以下内容：

1）披露REP 301-LTF和REP 401研究的最终完整随访结果，表明HBV和HDV感染的稳定功能治愈率很高。

2）分析表明，在基于NAP的联合用药期间，在不存在HBsAg的情况下发生的转氨酶耀斑与该治疗上里程碑预测HBV和HDV感染的病毒学控制和功能治愈的能力之间存在安全和有益的关系。

Replicor的演示文稿将在公司网站www.replicor.com/science/conference-presentations上发布后提供。有关2019 HEPDART会议的更多信息，请访问：https：//hepdart.com/

关于复制品

Replicor是一家私有生物制药公司，在开发HBV和HDV的治疗方法方面拥有最先进的动物和人类临床数据。该公司致力于加快针对HBV和HBV / HDV合并感染患者的有效治疗方法的开发。有关Replicor的更多信息，请访问我们的网站www.replicor.com。

hchu

面对千亿市场，真沉得住气。

乙肝人1949

放了一个麻雷子，不知道响或者不响

边缘

这个大忽悠。

hp121

中外都有忽悠

灵魂不屈

感谢分享。